NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer
Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m C) in cervic...
Saved in:
Published in | Molecular cancer Vol. 23; no. 1; pp. 139 - 16 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
05.07.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m
C) in cervical cancer radiosensitivity.
The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m
C sequencing, mRNA sequencing, and RNA immunoprecipitation.
We found a higher abundance of m
C modification in resistant CC samples, and NSUN6 was the essential m
C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m
C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m
C modification of NDRG1 mRNA, and the m
C reader ALYREF bound explicitly to the m
C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.
Aberrant m
C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m
C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. |
---|---|
AbstractList | Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m
C) in cervical cancer radiosensitivity.
The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m
C sequencing, mRNA sequencing, and RNA immunoprecipitation.
We found a higher abundance of m
C modification in resistant CC samples, and NSUN6 was the essential m
C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m
C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m
C modification of NDRG1 mRNA, and the m
C reader ALYREF bound explicitly to the m
C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.
Aberrant m
C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m
C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m.sup.5C) in cervical cancer radiosensitivity. The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m.sup.5C sequencing, mRNA sequencing, and RNA immunoprecipitation. We found a higher abundance of m.sup.5C modification in resistant CC samples, and NSUN6 was the essential m.sup.5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m.sup.5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m.sup.5C modification of NDRG1 mRNA, and the m.sup.5C reader ALYREF bound explicitly to the m.sup.5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Aberrant m.sup.5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m.sup.5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Abstract Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity. Methods The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation. Results We found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Conclusions Aberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity.BACKGROUNDRadioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m5C) in cervical cancer radiosensitivity.The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation.METHODSThe abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m5C sequencing, mRNA sequencing, and RNA immunoprecipitation.We found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.RESULTSWe found a higher abundance of m5C modification in resistant CC samples, and NSUN6 was the essential m5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m5C modification of NDRG1 mRNA, and the m5C reader ALYREF bound explicitly to the m5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer.Aberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis.CONCLUSIONSAberrant m5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to explore the biological function and clinical significance of 5-methylcytosine (m.sup.5C) in cervical cancer radiosensitivity. Methods The abundance of RNA modification in radiotherapy-resistant and sensitive CC specimens was quantified by liquid chromatography-tandem mass spectrometry. The essential RNA modification-related genes involved in CC radiosensitivity were screened via RNA sequencing. The effect of NSUN6 on radiosensitivity was verified in CC cell lines, cell-derived xenograft (CDX), and 3D bioprinted patient-derived organoid (PDO). The mechanisms of NSUN6 in regulating CC radiosensitivity were investigated by integrative m.sup.5C sequencing, mRNA sequencing, and RNA immunoprecipitation. Results We found a higher abundance of m.sup.5C modification in resistant CC samples, and NSUN6 was the essential m.sup.5C-regulating gene concerning radiosensitivity. NSUN6 overexpression was clinically correlated with radioresistance and poor prognosis in cervical cancer. Functionally, higher NSUN6 expression was associated with radioresistance in the 3D PDO model of cervical cancer. Moreover, silencing NSUN6 increased CC radiosensitivity in vivo and in vitro. Mechanistically, NDRG1 was one of the downstream target genes of NSUN6 identified by integrated m.sup.5C-seq, mRNA-seq, and functional validation. NSUN6 promoted the m.sup.5C modification of NDRG1 mRNA, and the m.sup.5C reader ALYREF bound explicitly to the m.sup.5C-labeled NDRG1 mRNA and enhanced NDRG1 mRNA stability. NDRG1 overexpression promoted homologous recombination-mediated DNA repair, which in turn led to radioresistance in cervical cancer. Conclusions Aberrant m.sup.5C hypermethylation and NSUN6 overexpression drive resistance to radiotherapy in cervical cancer. Elevated NSUN6 expression promotes radioresistance in cervical cancer by activating the NSUN6/ALYREF-m.sup.5C-NDRG1 pathway. The low expression of NSUN6 in cervical cancer indicates sensitivity to radiotherapy and a better prognosis. Keywords: Cervical cancer, Radioresistance, m.sup.5C modification, NSUN6, 3D bioprinted patient-derived organoid |
ArticleNumber | 139 |
Audience | Academic |
Author | Ke, Guihao Chen, Jiaxin Li, Jiajia Chen, Lihua Tang, Min Xia, Siyu Wu, Xiaohua Yu, Min Diao, Yixin Li, Jiana Zhu, Jun Liu, Chaohua Ni, Mengdong Xu, Fei |
Author_xml | – sequence: 1 givenname: Min surname: Yu fullname: Yu, Min – sequence: 2 givenname: Mengdong surname: Ni fullname: Ni, Mengdong – sequence: 3 givenname: Fei surname: Xu fullname: Xu, Fei – sequence: 4 givenname: Chaohua surname: Liu fullname: Liu, Chaohua – sequence: 5 givenname: Lihua surname: Chen fullname: Chen, Lihua – sequence: 6 givenname: Jiana surname: Li fullname: Li, Jiana – sequence: 7 givenname: Siyu surname: Xia fullname: Xia, Siyu – sequence: 8 givenname: Yixin surname: Diao fullname: Diao, Yixin – sequence: 9 givenname: Jiaxin surname: Chen fullname: Chen, Jiaxin – sequence: 10 givenname: Jun surname: Zhu fullname: Zhu, Jun – sequence: 11 givenname: Xiaohua surname: Wu fullname: Wu, Xiaohua – sequence: 12 givenname: Min surname: Tang fullname: Tang, Min – sequence: 13 givenname: Jiajia surname: Li fullname: Li, Jiajia – sequence: 14 givenname: Guihao surname: Ke fullname: Ke, Guihao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38970106$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kt9rFDEQxxep2B_6D_ggC774sjWzm2SzT3JUrYVyQrXPIZlNrim7mzPJFe6_N3vXSk9EQsgw-c6HSeZ7WhxNfjJF8RbIOYDgHyPUHW0qUtO8CWNV_aI4AdryirJOHD2Lj4vTGO8JgVa09FVx3IiuJUD4SWGXP26XvBpN71QyfclymO62A26Tj24y5eh7Zx2q5PxUelsuP99cQjneLBflOvjRJxPLoHrng4kuJjWhKd1UogkPuWoocc6E18VLq4Zo3jyeZ8Xt1y8_L75V198vry4W1xWyhqcKtNWaWd21VGuluRDcgO6JVtRaRojgCniHjCMVxCrosVWUakE6tEYxaM6Kqz239-peroMbVdhKr5zcJXxYSRWSw8FIJBaQW1AENRUMOsuQCUrbzrZNq21mfdqz1hud_wfNlIIaDqCHN5O7kyv_IAHqmuWBZMKHR0LwvzYmJjm6iGYY1GT8JsqGtLwWXECdpe_30pXKvbnJ-ozEWS4XgpCaA2lm1fk_VHn1ZnSY3WFdzh8UvHv-hj_NPxkgC8RegMHHGIyV6NJu2JnsBglEzl6Te6_J7DW585qc2fVfpU_0_xT9BqXO1jE |
CitedBy_id | crossref_primary_10_3390_biomedicines12112533 crossref_primary_10_1016_j_molmed_2024_11_001 crossref_primary_10_1007_s10565_024_09924_y crossref_primary_10_1002_mc_23857 crossref_primary_10_1038_s41698_024_00737_0 |
Cites_doi | 10.1038/s41556-019-0361-y 10.1038/cr.2017.55 10.1093/nar/gkx473 10.1073/pnas.1314469111 10.1182/blood.2022015752 10.1016/j.stem.2019.10.010 10.1186/s12943-021-01340-8 10.1038/s41598-023-45144-w 10.1038/s41416-023-02542-1 10.1038/s41388-021-01735-3 10.1056/NEJMra1805035 10.1038/s41388-023-02707-5 10.1038/s41392-020-00450-x 10.1186/s13046-018-0758-7 10.1073/pnas.2116251119 10.1093/nar/gks144 10.1038/s41392-023-01639-6 10.1038/s41392-020-0150-x 10.1016/j.cmet.2023.07.009 10.1038/s41418-023-01223-z 10.1159/000535479 10.1001/jama.298.19.2289 10.1093/nar/gkaa1193 10.1124/pharmrev.122.000795 10.1186/s12943-023-01780-4 10.1016/j.drup.2023.101033 10.1186/s12943-023-01801-2 10.1002/ctm2.545 10.1016/j.redox.2023.102975 10.1002/ctm2.1466 10.1002/mco2.55 10.1093/nsr/nwaa273 10.1038/s41388-021-01978-0 10.1002/advs.202003897 10.1038/s41388-020-1250-3 10.1016/j.ccell.2023.04.019 10.1016/j.ymthe.2023.07.018 10.7150/ijbs.79205 10.1016/j.bbcan.2023.188871 10.1158/1078-0432.CCR-18-3590 10.1016/j.ebiom 10.1016/S0140-6736(18)32470-X 10.1186/s13046-019-1268-y 10.1158/0008-5472.CAN-21-0871 10.1186/s12943-023-01782-2 10.1111/jcmm.17826 10.1038/cr.2017.73 10.1038/s41580-019-0168-5 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s12943-024-02055-2 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1476-4598 |
EndPage | 16 |
ExternalDocumentID | oai_doaj_org_article_c0f1c6f1a0cb48519f5c584479f737bf PMC11225205 A800261032 38970106 10_1186_s12943_024_02055_2 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 82272898 – fundername: Science and Technology Commission of Shanghai Municipality grantid: 22YF1409100 – fundername: National Natural Science Foundation of China grantid: 82272682 – fundername: National Natural Science Foundation of China grantid: 82303661 |
GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c536t-1bfbb5fb974bbab6886e1bd0ba4ff50086a169c56c480fa1dc7a44b809cfea513 |
IEDL.DBID | M48 |
ISSN | 1476-4598 |
IngestDate | Wed Aug 27 01:31:44 EDT 2025 Thu Aug 21 18:32:24 EDT 2025 Mon Jul 21 09:20:31 EDT 2025 Tue Jun 17 22:08:47 EDT 2025 Tue Jun 10 21:02:56 EDT 2025 Mon Jul 21 06:04:06 EDT 2025 Thu Apr 24 23:01:37 EDT 2025 Tue Jul 01 01:01:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Radioresistance 3D bioprinted patient-derived organoid NSUN6 Cervical cancer m5C modification |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c536t-1bfbb5fb974bbab6886e1bd0ba4ff50086a169c56c480fa1dc7a44b809cfea513 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/c0f1c6f1a0cb48519f5c584479f737bf |
PMID | 38970106 |
PQID | 3076286812 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c0f1c6f1a0cb48519f5c584479f737bf pubmedcentral_primary_oai_pubmedcentral_nih_gov_11225205 proquest_miscellaneous_3076286812 gale_infotracmisc_A800261032 gale_infotracacademiconefile_A800261032 pubmed_primary_38970106 crossref_citationtrail_10_1186_s12943_024_02055_2 crossref_primary_10_1186_s12943_024_02055_2 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-07-05 |
PublicationDateYYYYMMDD | 2024-07-05 |
PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Molecular cancer |
PublicationTitleAlternate | Mol Cancer |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | SE Bates (2055_CR10) 2020; 383 N Gabriel (2055_CR8) 2022; 82 S Javed (2055_CR48) 2024; 130 PA Cohen (2055_CR1) 2019; 393 X Chen (2055_CR13) 2019; 21 S-J Chen (2055_CR41) 2024; 69 D Yan (2055_CR42) 2023; 27 W Jiang (2055_CR2) 2024; 72 R-J Liu (2055_CR22) 2017; 45 M Ni (2055_CR29) 2021; 40 M Buttarelli (2055_CR46) 2019; 38 JK Schwarz (2055_CR3) 2007; 298 F Xu (2055_CR24) 2021; 20 H Zhuang (2055_CR7) 2023; 22 C Macedo-Silva (2055_CR9) 2023; 8 D Frank (2055_CR33) 2023; 142 YP Liu (2055_CR6) 2021; 2 Z Deng (2055_CR30) 2023; 75 D Dominissini (2055_CR18) 2017; 27 J Liu (2055_CR15) 2021; 8 Z Lu (2055_CR43) 2024; 33 Z Liu (2055_CR35) 2021; 11 S Zaccara (2055_CR31) 2019; 20 X Yang (2055_CR16) 2017; 27 T Selmi (2055_CR14) 2021; 49 Y Chen (2055_CR21) 2023; 19 H Yang (2055_CR37) 2022; 119 X Zhao (2055_CR45) 2023; 1878 M Weiler (2055_CR32) 2014; 111 ZN Abbas (2055_CR27) 2023; 13 CA Pasch (2055_CR25) 2019; 25 L Tang (2055_CR4) 2018; 37 R-X Huang (2055_CR28) 2020; 5 X Sun (2055_CR36) 2023; 31 P Li (2055_CR38) 2023; 13 X Jiang (2055_CR11) 2021; 6 Y Yao (2055_CR26) 2020; 26 M-KN Hutchinson (2055_CR23) 2020; 39 R Yang (2055_CR44) 2021; 63 L Wang (2055_CR34) 2023; 41 Y Wu (2055_CR5) 2023; 22 Y Wang (2055_CR17) 2023; 22 Y Zhang (2055_CR40) 2023; 30 JE Squires (2055_CR12) 2012; 40 T Chen (2055_CR39) 2023; 35 J Su (2055_CR20) 2021; 40 K Liu (2055_CR19) 2023; 42 Y Zhao (2055_CR47) 2021; 8 |
References_xml | – volume: 21 start-page: 978 issue: 8 year: 2019 ident: 2055_CR13 publication-title: Nat Cell Biol doi: 10.1038/s41556-019-0361-y – volume: 27 start-page: 606 issue: 5 year: 2017 ident: 2055_CR16 publication-title: Cell Res doi: 10.1038/cr.2017.55 – volume: 45 start-page: 6684 issue: 11 year: 2017 ident: 2055_CR22 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkx473 – volume: 111 start-page: 409 issue: 1 year: 2014 ident: 2055_CR32 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1314469111 – volume: 142 start-page: 2175 issue: 25 year: 2023 ident: 2055_CR33 publication-title: Blood doi: 10.1182/blood.2022015752 – volume: 26 start-page: 17 issue: 1 year: 2020 ident: 2055_CR26 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2019.10.010 – volume: 20 start-page: 1 year: 2021 ident: 2055_CR24 publication-title: Mol Cancer doi: 10.1186/s12943-021-01340-8 – volume: 13 start-page: 18380 issue: 1 year: 2023 ident: 2055_CR27 publication-title: Sci Rep doi: 10.1038/s41598-023-45144-w – volume: 130 start-page: 467 issue: 3 year: 2024 ident: 2055_CR48 publication-title: Br J Cancer doi: 10.1038/s41416-023-02542-1 – volume: 40 start-page: 2711 issue: 15 year: 2021 ident: 2055_CR29 publication-title: Oncogene doi: 10.1038/s41388-021-01735-3 – volume: 383 start-page: 650 issue: 7 year: 2020 ident: 2055_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMra1805035 – volume: 42 start-page: 1980 issue: 24 year: 2023 ident: 2055_CR19 publication-title: Oncogene doi: 10.1038/s41388-023-02707-5 – volume: 6 start-page: 74 issue: 1 year: 2021 ident: 2055_CR11 publication-title: Signal Transduct Target Therapy doi: 10.1038/s41392-020-00450-x – volume: 37 start-page: 1 year: 2018 ident: 2055_CR4 publication-title: J Experimental Clin Cancer Res doi: 10.1186/s13046-018-0758-7 – volume: 119 start-page: e2116251119 issue: 12 year: 2022 ident: 2055_CR37 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.2116251119 – volume: 40 start-page: 5023 issue: 11 year: 2012 ident: 2055_CR12 publication-title: Nucleic Acids Res doi: 10.1093/nar/gks144 – volume: 8 start-page: 395 issue: 1 year: 2023 ident: 2055_CR9 publication-title: Signal Transduct Target Therapy doi: 10.1038/s41392-023-01639-6 – volume: 5 start-page: 60 issue: 1 year: 2020 ident: 2055_CR28 publication-title: Signal Transduct Target Therapy doi: 10.1038/s41392-020-0150-x – volume: 35 start-page: 1782 issue: 10 year: 2023 ident: 2055_CR39 publication-title: Cell Metabol doi: 10.1016/j.cmet.2023.07.009 – volume: 30 start-page: 2462 issue: 12 year: 2023 ident: 2055_CR40 publication-title: Cell Death Differ doi: 10.1038/s41418-023-01223-z – volume: 33 start-page: 56 issue: 1 year: 2024 ident: 2055_CR43 publication-title: Med Principles Pract doi: 10.1159/000535479 – volume: 298 start-page: 2289 issue: 19 year: 2007 ident: 2055_CR3 publication-title: JAMA doi: 10.1001/jama.298.19.2289 – volume: 49 start-page: 1006 issue: 2 year: 2021 ident: 2055_CR14 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa1193 – volume: 75 start-page: 1007 issue: 5 year: 2023 ident: 2055_CR30 publication-title: Pharmacol Rev doi: 10.1124/pharmrev.122.000795 – volume: 22 start-page: 81 issue: 1 year: 2023 ident: 2055_CR17 publication-title: Mol Cancer doi: 10.1186/s12943-023-01780-4 – volume: 72 start-page: 101033 year: 2024 ident: 2055_CR2 publication-title: Drug Resist Updates doi: 10.1016/j.drup.2023.101033 – volume: 22 start-page: 96 issue: 1 year: 2023 ident: 2055_CR5 publication-title: Mol Cancer doi: 10.1186/s12943-023-01801-2 – volume: 11 start-page: e545 issue: 9 year: 2021 ident: 2055_CR35 publication-title: Clin Translational Med doi: 10.1002/ctm2.545 – volume: 69 start-page: 102975 year: 2024 ident: 2055_CR41 publication-title: Redox Biol doi: 10.1016/j.redox.2023.102975 – volume: 13 start-page: e1466 issue: 11 year: 2023 ident: 2055_CR38 publication-title: Clin Translational Med doi: 10.1002/ctm2.1466 – volume: 2 start-page: 315 issue: 3 year: 2021 ident: 2055_CR6 publication-title: MedComm doi: 10.1002/mco2.55 – volume: 8 start-page: nwaa273 issue: 6 year: 2021 ident: 2055_CR15 publication-title: Natl Sci Rev doi: 10.1093/nsr/nwaa273 – volume: 40 start-page: 5814 issue: 39 year: 2021 ident: 2055_CR20 publication-title: Oncogene doi: 10.1038/s41388-021-01978-0 – volume: 8 start-page: 2003897 issue: 11 year: 2021 ident: 2055_CR47 publication-title: Adv Sci doi: 10.1002/advs.202003897 – volume: 39 start-page: 3638 issue: 18 year: 2020 ident: 2055_CR23 publication-title: Oncogene doi: 10.1038/s41388-020-1250-3 – volume: 41 start-page: 1294 issue: 7 year: 2023 ident: 2055_CR34 publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.04.019 – volume: 31 start-page: 2633 issue: 9 year: 2023 ident: 2055_CR36 publication-title: Mol Ther doi: 10.1016/j.ymthe.2023.07.018 – volume: 19 start-page: 691 issue: 2 year: 2023 ident: 2055_CR21 publication-title: Int J Biol Sci doi: 10.7150/ijbs.79205 – volume: 1878 start-page: 188871 issue: 3 year: 2023 ident: 2055_CR45 publication-title: Biochim et Biophys Acta (BBA)-Reviews Cancer doi: 10.1016/j.bbcan.2023.188871 – volume: 25 start-page: 5376 issue: 17 year: 2019 ident: 2055_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-3590 – volume: 63 start-page: 103195 year: 2021 ident: 2055_CR44 publication-title: EBioMedicine doi: 10.1016/j.ebiom – volume: 393 start-page: 169 issue: 10167 year: 2019 ident: 2055_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(18)32470-X – volume: 38 start-page: 1 year: 2019 ident: 2055_CR46 publication-title: J Experimental Clin Cancer Res doi: 10.1186/s13046-019-1268-y – volume: 82 start-page: 2019 issue: 10 year: 2022 ident: 2055_CR8 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-0871 – volume: 22 start-page: 91 issue: 1 year: 2023 ident: 2055_CR7 publication-title: Mol Cancer doi: 10.1186/s12943-023-01782-2 – volume: 27 start-page: 2398 issue: 16 year: 2023 ident: 2055_CR42 publication-title: J Cell Mol Med doi: 10.1111/jcmm.17826 – volume: 27 start-page: 717 issue: 6 year: 2017 ident: 2055_CR18 publication-title: Cell Res doi: 10.1038/cr.2017.73 – volume: 20 start-page: 608 issue: 10 year: 2019 ident: 2055_CR31 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/s41580-019-0168-5 |
SSID | ssj0017874 |
Score | 2.499237 |
Snippet | Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory... Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a... Abstract Background Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 139 |
SubjectTerms | 3D bioprinted patient-derived organoid 5-Methylcytosine - analogs & derivatives 5-Methylcytosine - metabolism Analysis Animals Cell Cycle Proteins - genetics Cell Cycle Proteins - metabolism Cell Line, Tumor Cervical cancer DNA Drug resistance Ethylenediaminetetraacetic acid Female Gene Expression Regulation, Neoplastic Genes Humans Intracellular Signaling Peptides and Proteins - genetics Intracellular Signaling Peptides and Proteins - metabolism Liquid chromatography m5C modification Mass spectrometry Messenger RNA Methyltransferases - genetics Methyltransferases - metabolism Mice NSUN6 Prognosis Radiation Radiation Tolerance - genetics Radioresistance RNA sequencing RNA, Messenger - genetics RNA, Messenger - metabolism Uterine Cervical Neoplasms - genetics Uterine Cervical Neoplasms - metabolism Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - radiotherapy Xenograft Model Antitumor Assays |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl0NJLadOX27SoUOihmFheSZaP20caCvEh7UJuQiNLdCGxw-7msP--M7J3WVNoLz34Ysl4pBnNfIPmwdh7E6GsY6iRA1XIJUCVA7rLudSqFs5FbQIlOF80-nwhv1-pq4NWXxQTNpQHHjbu1BdReB2FKzxIhAd1VB6NpqzqWM0qiKR90ebtnKnx_gDFUO5SZIw-XaNVk3RfKfEplMrLiRlK1fr_1MkHRmkaMHlggc4es0cjdOTzgeQn7F7ojtn9oZnk9pg9uBivyZ-y2PxYNDpPWSGIKLnKqVH09tpvNz3FufObvqUQocQV3kfefLn8JvjNZTPntyk-L6z5yrXLHp1xApgoGXzZcZ8UC9Lg6c3qGVucff35-TwfGyrkXs30JhcQAVQE9CEAHGhjdBDQFuBkjIq8Gyd07ZX20hTRidZXTkowRe1jcErMnrOjru_CS8YNxLKCVgTEMzL6ForWCfCEltroKpExsdtf68dq49T04tomr8NoO_DEIk9s4oktM_Zx_83tUGvjr7M_Edv2M6lOdnqB0mNH6bH_kp6MfSCmWzrNSJ53Y1ICLpLqYtm5SU5qMcPfnUxm4in0k-F3O7GxNESha13o79YWlSil_yKQytiLQYz2NCNarMgpz5iZCNhkUdORbvkrFQFHnFwq3IlX_2MbXrOHZTocVV6oE3a0Wd2FNwi2NvA2navfUUsmYg priority: 102 providerName: Directory of Open Access Journals |
Title | NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38970106 https://www.proquest.com/docview/3076286812 https://pubmed.ncbi.nlm.nih.gov/PMC11225205 https://doaj.org/article/c0f1c6f1a0cb48519f5c584479f737bf |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfGJhAvCAaMwKiChMQDCsStv_KAUAcbE1IjVKjUN8t2bKjUJaPtJPrfc-emZRETEg95iZ3E9t35fhffByEvVbD9IvgCKCB9xqyVmQVzOWOCF9SYIJTHAOdRKc4n7POUT_fIttxRu4DLG007rCc1Wczf_Pq5fg8C_y4KvBJvl6CzGJ5GMrhyzjPYkg9AM0kU1BH7c6oAzBlPmRkOhhdqG0Rz4zs6iirm8_97176mtrouldd01Nl9cq8Fl-lwww0PyJ6vD8ntTbnJ9SG5M2oP0h-SUH6dlCKLcSOAOVOeYSnp9dytVw16wqcXTYVORJFuaRPS8uP4E00vxuUwvYwefH6ZLkw1a8BcRwgKvJPO6tTFrQfG4PDO4hGZnJ1--3CetSUXMscHYpVRG6zlwYKVYa2xQinhqa1ya1gIHO0fQ0XhuHBM5cHQyknDmFV54YI3nA4ek_26qf0Tkiob-tJW1APiYcFVNq8MtQ7xVBWMpAmh2_XVrs1HjmUx5jraJUroDU000ERHmuh-Ql7vnrncZOP4Z-8TJNuuJ2bSjjeaxXfdCqZ2eaBOBGpyZxnAzyJwB6CMySLIgbQhIa-Q6Bo5EIbnTBu2AJPEzFl6qKIZmw_gc8edniCnrtP8Yss2GpvQua32zdVSwzaLAcIAtRJytGGj3ZgBT0o02xOiOgzWmVS3pZ79iGnCAUn3OazE0_9atGfkbj9Kgcxyfkz2V4sr_xxw18r2yC05lT1ycHJafhn34t-LXhSw33S7Kfs |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NSUN6-mediated+5-methylcytosine+modification+of+NDRG1+mRNA+promotes+radioresistance+in+cervical+cancer&rft.jtitle=Molecular+cancer&rft.au=Yu%2C+Min&rft.au=Ni%2C+Mengdong&rft.au=Xu%2C+Fei&rft.au=Liu%2C+Chaohua&rft.date=2024-07-05&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-024-02055-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_024_02055_2 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon |